SUPERSTRING CAPITAL MANAGEMENT LP

Position in SVRA — Savara Inc

CIK 1931118 NEW YORK, NY

Position in SVRA

as of Mar 31, 2026 · filed May 14, 2026 Compact

Position Value

$8,659,434

+$2,657,456 QoQ

Shares Held

1,585,977

+59.3% QoQ

Ownership

0.774%

of shares outstanding

% of Portfolio

6.19%

of 13F equity value

Holder Rank

#27

of 184 holders

Holding Since

Dec 2023

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

SUPERSTRING CAPITAL MANAGEMENT LP holds $130,439,416 across 32 Biotechnology names. SVRA ranks #4 (6.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	SMMT	Summit Therapeutics Inc.	892,873	$16,928,872
2	IMVT	Immunovant, Inc.	357,606	$8,882,933
3	COGT	Cogent Biosciences, Inc.	225,158	$8,666,331
4	SVRA	Savara Inc This page	1,585,977	$8,659,434
5	URGN	UroGen Pharma Ltd.	387,371	$6,964,930
6	DFTX	Definium Therapeutics, Inc.	351,461	$6,642,612
7	VIR	Vir Biotechnology, Inc.	730,548	$6,545,710
8	PCVX	Vaxcyte, Inc.	110,454	$6,418,481

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$8,659,434	1,585,977	+59.3%	Shares	Sole	2026-05-14
2025-12-31	$6,001,978	995,353	-24.0%	Shares	Sole	2026-02-17
2025-09-30	$4,673,972	1,309,236	+17.4%	Shares	Sole	2025-11-14
2025-06-30	$2,543,064	1,115,379	+15.4%	Shares	Sole	2025-08-14
2025-03-31	$2,676,382	966,203	+90.1%	Shares	Sole	2025-05-15
2024-12-31	$1,560,597	508,338	+154.2%	Shares	Sole	2025-02-14
2024-09-30	$848,000	200,000	0.0%	Shares	Sole	2024-11-14
2024-06-30	$806,000	200,000	-90.3%	Shares	Sole	2024-08-14
2024-03-31	$10,284,417	2,065,144	+153.6%	Shares	Sole	2024-05-15
2023-12-31	$3,827,050	814,266	—	Shares	Sole	2024-02-14
No filing history on record for this holder in this stock.